RVPH
+1
Aug 20, 2026
Reviva pushed its Phase 3 back a year, and the stock is down ~27% since my June write-up. Two developments matter more: (1) a patent filing that stretches exclusivity to 2046 and (2) evidence Teva has studied brilaroxazine since 2023.
BRUN
+5
Aug 16, 2026
Five quarterly updates on names from the write-up archive. I compare against guidance and discuss what actually matters underneath the headline numbers.
AWMLF
+1
Aug 13, 2026
A US$28M company owns the largest known undeveloped indium resource in the US. The US imports 100% of its indium, China controls 70% of supply, and the Pentagon has started soliciting purchases for the stockpile.
CELH
+6
Aug 10, 2026
A very busy earnings week across the names from past write-ups. The market mostly traded the headline while the filings told a more specific story.

Write-ups and models on asymmetric stocks and macro themes. Built on 10+ years studying top investors/funds, and 500,000+ words of published guides.